Novel 1′,1′-chain substituted Δ8-tetrahydrocannabinols

https://doi.org/10.1016/S0960-894X(02)00785-0Get rights and content

Abstract

1′,1′-Cyclopropyl side chain substituents enhance the affinities of Δ8-tetrahydrocannabinol and respective cannabidiol analogues for the CB1 and CB2 cannabinoid receptors. The results support the hypothesis for a subsite within CB1 and CB2 binding domain at the level of the benzylic side chain carbon in the tetrahydrocannabinol and cannabidiol series. Efficient procedures for the synthesis of 1′,1′-cyclopropyl analogues are described.

Section snippets

Acknowledgments

This work was supported by the National Hellenic Research Foundation and by grants from the National Institute on Drug Abuse DA03801, DA09158 and DA07215. We also thank Joy Erickson for her technical support.

References (16)

  • R.G Pertwee

    Pharmacol. Ther.

    (1997)
  • A Makriyannis et al.

    Life Sci.

    (1990)
    R.K Razdan

    Pharmacol. Rev.

    (1986)
    A.D Khanolkar et al.

    Chem. Phys. Lipids

    (2000)
  • D.P Papahatjis et al.

    J. Med. Chem.

    (1998)
  • C.G Pitt et al.

    J. Lab. Comp.

    (1975)
  • W.A Devane et al.

    Mol. Pharmacol.

    (1988)
  • S Munro et al.

    Nature

    (1993)
  • R Adams et al.

    J. Am. Chem. Soc.

    (1949)
    J.W Huffman et al.

    Bioorg. Med. Chem.

    (1998)
    J Busch-Petersen et al.

    J. Med. Chem.

    (1996)
    A.D Khanolkar et al.

    Bioorg. Med. Chem. Lett.

    (1999)
    B.R Martin et al.

    J. Pharmacol. Exp. Ther.

    (1999)
    M Singer et al.

    J. Med. Chem.

    (1998)
There are more references available in the full text version of this article.

Cited by (46)

  • Synthesis and characterization of a compact tricyclic resorcinol from (+)- and (-)-3-pinanol

    2012, Tetrahedron Letters
    Citation Excerpt :

    In the course of our program aimed at developing potent and selective cannabinoids we have focused on analogs with conformationally restricted and bulky side chains.5–14 In this regard, the aliphatic C3 side chain was substituted with C1′ cyclic groups,5–8 or partially immobilized by a fused six-membered ring,10,15 or replaced by the bulky adamantyl, heteroadamantyl, bornyl, and isobornyl substituents.11–14 Some of these analogs showed enhanced CB receptor subtype selectivity and affinity as well as remarkable in vivo potency.

  • Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2

    2011, European Journal of Medicinal Chemistry
    Citation Excerpt :

    A representative set of 64 CB2 ligands was selected (see Fig. 1 and Table S1), taking in no account their functional activity, among a number of 4-quinolone-3-carboxamides recently synthesized in our laboratory (23–39 and 64) [31] and derivatives belonging to different structural classes already reported in the literature (1–13, 17 and WIN55212-2 (58) [28], JWH-015 (14) and CP-55,940 (55) [32], JWH-181 (15) and JWH-007 (16) [19], AM1241 (18) [33], AM630 (19) [34], 20–22 and 40–42 [7c], 43–45 [20], L759633 (46) and L759656 (47) [35], 48–51 [21], O-1057 (52) [36], AMG41 (53) [22], JWH-133 (54) [23], AM855 (56) [24], BAY593074 (57) [37], gp1a (59) [38], 60 [39], SR144528 (61) [40], HU-308 (62) [41], and GW405833 (63) [42]). The binding affinities of all these compounds for human recombinant CB1 and CB2 receptors (Ki values) have been measured according to the same protocol, by displacement of the radioligand [3H]-CP-55,940 [7c,19–24,28,31–42] and are shown in Table 1 (second and third columns). Our selection was restrained to compounds showing high CB2 affinity (Ki values ≤ 56.7 nM) and CB1 affinity covering approximately four orders of magnitude (Ki values ranging from 0.5 to >10,000 nM).

View all citing articles on Scopus
View full text